KIR2DL2

KIR2DL2 Molekülinformation

Englischer Name	Killer cell immunoglobulin-like receptor 2DL2	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1	Target-Alias	CD158b1 Antigen，CD158b，P58.2，Receptors， KIR2DL2，CD158k，Cl-43，p58 NK receptor CL-43，CD158B1，Natural killer-associated transcript 6，NKAT6，Killer cell immunoglobulin-like receptor 2DL2，KIR2DL2，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 2，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 2，P58 Natural Killer Cell Receptor Clone CL-43，CD158 Antigen-Like Family Member B1，MHC Class I NK Cell Receptor，NKAT-6
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Killer cell immunoglobulin-like receptor 2DL2
Target-Alias	CD158b1 Antigen，CD158b，P58.2，Receptors， KIR2DL2，CD158k，Cl-43，p58 NK receptor CL-43，CD158B1，Natural killer-associated transcript 6，NKAT6，Killer cell immunoglobulin-like receptor 2DL2，KIR2DL2，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 2，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 2，P58 Natural Killer Cell Receptor Clone CL-43，CD158 Antigen-Like Family Member B1，MHC Class I NK Cell Receptor，NKAT-6
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

KIR2DL2 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
Fc Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
KI2-H5255	Human	HEK293	Human KIR2DL2 / CD158b1 / NKAT-6 Protein, Fc Tag				In den Warenkorb legen

Gesamtmenge1

KIR2DL2 Molekülhintergrund

Killer cell immunoglobulin-like receptor 2DL2(KIR2DL2), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. KIR2DL2 and KIR2DL3, regulate the activation of natural killer cells (NK) by interacting with the human leukocyte antigen-C1 (HLA-C1) group of molecules. KIR2DL2, KIR2DL3 and HLA-C1 are highly polymorphic, with this variation being associated with differences in the onset and progression of some human diseases.

KIR2DL2 Molekülalias

CD158b1

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Lirilumab	IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015	Phase 2 Clinical	Novo Nordisk A/S	Bone Marrow Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Smoldering Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms	Details